Posted in | News | Laser | Medical Optics

AANS 2016: New Results Support Use of Monteris Medical’s NeuroBlate System for Brain Lesions

Monteris Medical today announced new data from two separate studies supporting the use of its NeuroBlate® System for brain lesions were presented at the American Association of Neurological Surgeons (AANS) 84th Annual Scientific Meeting, taking place from April 30 – May 4. Data evaluating customized 3D printed mini-platforms in laser interstitial thermal therapy (LITT) were also presented at the meeting.

Sujit S. Prabhu, M.D., F.R.C.S., F.A.A.N.S., Professor in the Department of Neurosurgery at The University of Texas MD Anderson Cancer Center, delivered an oral presentation today on 27 patients titled "Laser-Induced Thermal Therapy in Treatment of Recurrent Intracranial Metastatic Disease post-Stereotactic Radiosurgery."

Veronica L. Chiang, M.D., Associate Professor of Neurosurgery and of Therapeutic Radiology, Director of Stereotactic Radiosurgery, and Medical Director at the Yale-New Haven Hospital Gamma Knife Center, reported preliminary results titled "Laser Ablation After Stereotactic Radiosurgery."

"The NeuroBlate System has broad potential and the data presented at this conference add to the growing body of scientific and clinical evidence that support the use of this minimally invasive, innovative approach in a variety of brain lesions," said Daryle Petersen, Vice President of Clinical Affairs at Monteris Medical.

Additionally, Joseph S. Neimat, M.D., Professor and Chairman at the Center for Advanced Neurosurgery in the Department of Neurological Surgery at University of Louisville in Kentucky presented results from a study evaluating customized 3D mini-platforms in LITT. In a poster presentation, titled "Use of Customized 3-D Printed Platforms for Targeting in Laser Interstitial Thermal Therapy," described the use of custom 3D mini-platforms to target LITT in 9 patients. Such platforms have been used extensively to accurately position probes used in deep brain stimulation surgery and offer a promising approach to increase the precision of catheter placement within the brain during LITT procedures. The results show that laser placement was successful in all 9 patients, with good accuracy. There were no complications or intraoperative frame instability. The total frame cost per procedure was less than $6,000. Study investigators concluded that customized 3D printed platforms can provide accurate, simple, and rapid implantation of laser catheters for LITT procedures. They also note that the versatility of the design platform should enable future modifications as LITT technology evolves.

"These results demonstrate that customized printed 3D platforms can provide accurate, non-complex and rapid implantation of the laser catheter for performing LITT," said Dr. Neimat. "The versatility of the platform allows for both growth and flexible, iterative design modifications as LITT technology continues to evolve."

About the NeuroBlate® System

The NeuroBlate System is FDA-cleared to ablate, necrotize or coagulate soft tissue encountered in the discipline of neurosurgery through the application of laser thermotherapy. NeuroBlate is a tool (as opposed to a "treatment") and is not intended to treat any specific disease. Physicians should use their clinical judgment and experience when deciding whether to use NeuroBlate.

Since receiving FDA clearance in 2013, NeuroBlate has been used in more than 800 patient procedures across 35 installed systems in the U.S. and Canada.

Full prescribing information for the NeuroBlate System is available at

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.